-

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Novartis AG – NVS

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that the board of directors of Novartis may have breached its fiduciary duties to shareholders.

On June 25, 2020, the Company agreed to pay $225 million in criminal fines and disgorge $112 million in settling bribery allegations brought forth by the U.S. Department of Justice and the Securities and Exchange Commission. Novartis was under investigation for claims that: (1) the Company had bribed doctors and hospitals in Greece to prescribe “Novartis-branded pharmaceuticals”; (2) the Company had paid bribes in Vietnam to advance their business; and (3) the Company had falsified their financial records to conceal said activities. On this news, the Company’s share prices dropped by $2.50 over the following trading session.

Rosen Law Firm is preparing a securities lawsuit on behalf of Novartis shareholders. If you purchased securities of Novartis please visit the firm’s website at http://www.rosenlegal.com/cases-register-1887.html to join the securities action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contacts

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

The Rosen Law Firm, P.A.

NYSE:NVS

Release Versions

Contacts

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

Social Media Profiles
More News From The Rosen Law Firm, P.A.

Rosen Law Firm Encourages UP Fintech Holding Limited Investors to Inquire About Securities Class Action Investigation – TIGR

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of UP Fintech Holding Limited. (NASDAQ: TIGR) resulting from allegations that UP Fintech may have issued materially misleading business information to the investing public. So What: If you purchased UP Fintech securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fe...

Rosen Law Firm Encourages Futu Holdings Limited Investors to Inquire About Securities Class Action Investigation – FUTU

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Futu Holdings Limited (NASDAQ: FUTU) resulting from allegations that Futu may have issued materially misleading business information to the investing public. So What: If you purchased Futu securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The...

ATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 2024 and January 9, 2026. Atara describes itself as a company that “develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the U.S. and the United Kingdom.”For more information, submit a form, email attorney Phillip Kim, or give us...
Back to Newsroom